Ocular Theraputics and Drug DeliveryCRC Press, 12. pro 1995. - Broj stranica: 587 Since ocular therapeutics and drug delivery is a subject of interest to specialists from various disciplines such as chemical, biochemical, medical, pharmaceutical, and toxicological, it truly presents a unique situation requiring a multi-disciplinary approach in understanding and addressing various problems. Yet we see that scientists associated with these areas are working, by and large, independently of one another, thus limiting dissemination of knowledge, experience and ideas that would greatly enhance the overall progress in this area of research. Regrettably, the information currently available in ocular therapeutics and drug delivery, though extensive, is still fragmented into various disciplines making meaningful synthesis difficult. Several books are available that cover one or two aspects of the multi-disciplinary fields on an individual basis; however, none is available that covers all of them. The chapters contained in this book are specific to various interrelated areas of ocular therapeutics and drug delivery and are written by acknowledged experts from both academia and industry. The book itself is divided into five parts, namely: (I) overview,basic principles, and methodology; (II) pathopharmacology and clinical applications; (III) chemical/ biochemical approaches to ocular drug delivery; (IV) formulation and drug delivery considerations; and (V) industrial and regulatory considerations. Individual chapters in each section, apart from presenting a concise text, entail an extensive listing of references. |
Sadržaj
OCULAR THERAPEUTICS AND DRUG | 3 |
Ocular Drug Disposition | 9 |
Conventional Ophthalmic Dosage Forms | 15 |
Ocular Toxicity | 21 |
Wetting | 33 |
OilWater Partitioning | 39 |
BIOLOGICAL BARRIERS TO OCULAR DELIVERY | 51 |
Structure and Function | 75 |
Selected Case Studies of Prodrugs | 296 |
Future PerspectivesConclusions | 323 |
THE USE OF RETROMETABOLIC DRUG DESIGN | 335 |
The Inactive Metabolite Approach in the Design | 351 |
Conclusion | 358 |
DEVELOPMENT OF SOFT DRUGS | 363 |
Adaprolol Maleate | 372 |
Adjuvants | 379 |
Utility and Limitations | 88 |
Conclusions | 94 |
Appendix B | 107 |
Appendix F | 115 |
Appendix H | 122 |
PHARMACOKINETIC AND PHARMACODYNAMIC | 133 |
Ofloxacin | 142 |
DRUG METABOLIZING ENZYME SYSTEMS | 149 |
Enzymes | 157 |
ARTIFICIAL TEAR FORMULATIONS IRRIGATING | 171 |
Irrigating Solutions | 185 |
Contact Lens Products | 193 |
Conclusion | 204 |
CLINICAL PHARMACOLOGY OF THE ANTERIOR | 213 |
AntiInflammatory Agents | 222 |
AntiInfective Agents | 228 |
Conclusion | 239 |
RECENT DEVELOPMENTS IN ANTIGLAUCOMA | 245 |
PATHOLOGICAL | 265 |
Viral Retinitis | 272 |
CHEMICALBIOCHEMICAL APPROACHES TO OCULAR DRUG DELIVERY | 283 |
Enzymes Responsible for Bioconversion | 289 |
Sterility | 391 |
Conclusion | 398 |
POLYMERS IN OPHTHALMIC DRUG | 405 |
Applications of Polymers in the Eye | 417 |
Conclusions | 430 |
MICROPARTICULATES AS AN OCULAR | 441 |
Microparticulates as a Topical Ocular Delivery System | 448 |
Multiparticulate Manufacture | 455 |
PROTEIN AND PEPTIDE DRUG DELIVERY | 461 |
Ocular Administration of PeptidesProteins | 468 |
Specialized Delivery Systems | 477 |
Anatomy of the Cornea and Its Relation to Ocular | 499 |
Validation of in vitro Tests | 505 |
Conclusion | 512 |
PACKAGING ASPECTS OF OPHTHALMIC | 529 |
A BRIEF HISTORY OF DRUG REGULATION | 543 |
Regulatory IssuesRequirements | 549 |
Bioregulations | 557 |
Labeling Requirements | 564 |
573 | |
About the Editor 587 | |
Uobičajeni izrazi i fraze
acid activity administration adrenalone agents antibiotics application aqueous humor Arch artificial tear barrier benzalkonium chloride betaxolol bioavailability Bodor cells Chem chemical ciliary clinical coefficient conjunctiva contact lenses corneal epithelium corticosteroids dexamethasone diffusion dipivefrin dosage forms dose Draize Draize test drug delivery Drug Delivery Systems Endophthalmitis enzymes epinephrine epithelial Equation ester esterases Evaluation Eye Res eyedrops fluid formulation function glaucoma human hydrolysis hydrophilic increase injection instilled intraocular pressure Intravitreal irrigating solutions J. R. Robinson layer lens lipid lipophilic liposomes loteprednol loteprednol etabonate membrane metabolism microspheres molecular weight molecules Ocular Drug Delivery ocular tissues ointments Ophthalmol Ophthalmology peptides permeability Pharm pharmacokinetic Pharmacol Phenylephrine physiological Pigment pilocarpine polymers precorneal prodrugs protein Rabbit Eye reduced release retinal side effects sodium soft drug solubility sterilization steroids stroma studies surface surfactants systemic absorption tear film therapeutic therapy timolol tion topically applied toxicity Toxicol treatment viscosity vitro vivo
Popularni odlomci
Stranica 583 - The rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action.
Stranica 583 - ... intended to affect the structure or any function of the body of man or other animals, and which does not achieve any of its principal intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of any of its principal intended purposes.
Stranica 583 - ... extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses and the difference from the listed drug in the rate of absorption of the drug is intentional, is reflected in its proposed labeling, is not essential to the attainment of effective body drug concentrations on chronic use, and is considered medically insignificant for the drug.
Stranica 583 - Pharmacopeia, or any supplement to them, (2) intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals...
Stranica 583 - ... Active ingredient means any com-ponent that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body of man or other animals. The term includes those com-ponents that may undergo chemical change in the manufacture of the drug product and be present in the drug product in a modified form intended to furnish the specified activity or effect. (8) Inactive...